1591P Swedish national population-based study of direct oral anticoagulants and low molecular weight heparin treatment for thromboembolism in cancer patients: The OSCAR SWE study

Abstract

Cancer patients have high increased risk of Venous Thromboembolism (VTE) and treatments have changed lately. ISTH guidelines suggest rivaroxaban and edoxaban as alternatives to Low Molecular Weight Heparin (LMWH) for VTE treatment in certain cancers with low bleeding risk. However, little is known about safety and effectiveness from observational studies in routine clinical use. This is one of 3 studies in the OSCAR program. Optimal anticoagulation treatment duration in cancer patients remains an open question.